News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
New partnership model needed to explore kinases for cancer treatments
International leaders in drug discovery have warned that a huge reservoir of potential targets for cancer treatment will remain unexplored unless public funders, charities and pharmaceutical companies come together in a new model of large-scale partnership.
Bowel cancer gene discovery cracks mystery of families with a strong history of the disease
Scientists have discovered that two gene faults increase the risk of bowel cancer in families with a strong history of developing the disease, who, until now, had no explanation as to why their risk was greater.
Scientists discover intriguing new gene link to breast and ovarian cancer
A team of researchers led from the ICR, have found that mutations in a gene called PPM1D are linked to an increased risk of breast and ovarian cancer – through what may be a new mechanism of cancer development.
Prostate cancer drug benefits earlier-stage disease
Prostate cancer drug benefits earlier-stage disease
The ICR welcomes £100m investment in high-tech genome profiling for cancer patients.
The ICR welcomes £100m Government investment in high-tech genome profiling for cancer patients.
Fewer, bigger doses of radiotherapy benefit breast cancer patients
Women diagnosed with breast cancer can benefit from receiving fewer but higher doses of radiotherapy than is the international standard, according to long-term follow-up data of a major UK-wide trial led by the ICR.
Kidney cancer genetic risk discovery
Scientists at the ICR have found a new genetic variation which increases a person’s risk of developing the most common type of kidney cancer.
The ICR and Royal Marsden open groundbreaking facility bringing smart trials to the NHS
Scientists will monitor whether new-generation cancer drugs are successfully hitting their targets by simply plucking samples from patients’ eyebrows following the opening of a new world-class research facility at The Royal Marsden and its academic research partner, The Institute of Cancer Research, London.
Professor Paul Workman to join Innovation Debate 2012
Professor Paul Workman, Deputy Chief Executive and head of cancer therapeutics at The Institute of Cancer Research, London, will join the distinguished panel of world-leading experts and chairman Professor Jim Al-Khalili for The Innovation Debate 2012, taking place on 20th November at 4pm at the Royal Society in London and webcast live.
£1.2m grant to develop ICR-discovered drug
Professor Paul Workman, deputy chief executive of The Institute of Cancer Research, has welcomed the news that a drug designed and synthesised in his unit will benefit from a £1.2m grant from the UK government’s Biomedical Catalyst programme that should help speed its progress towards clinical trials.
Tackling cancer’s biggest challenge: Combination treatments offer hope to overcome drug resistance
The huge genetic diversity within tumours is threatening efforts to create personalised cancer treatments – but, as an article in Nature Biotechnology reveals, scientists at The Institute of Cancer Research in London believe powerful new technology will bring a solution.
Finding the right combination
The dream of a single pill to cure cancer, a magic bullet that stops the disease in its tracks, is one that now looks a little outdated.
